Sakamoto Eiji, Hasegawa Hiroshi, Komatsu Shunichiro, Norimizu Shinji, Shingu Yuji, Inaba Kazuki, Taguchi Yasuro, Ito Yuko, Watanabe Masahiro, Arimoto Atsuki, Isaji Takahiro, Makino Arano, Miura Yasutomo, Santo Masaki
Dept. of Surgery, Nagoya Daini Red Cross Hospital, Japan.
Gan To Kagaku Ryoho. 2013 May;40(5):613-6.
We retrospectively reviewed 500 cases who were implanted with subcutaneous central venous port(CV port)in our institution from Jan. 2007 to Nov. 2011, to investigate the complications arising after CV port implantation. The purpose of CV port implantation was chemotherapy access in 279 cases and home parenteral nutrition in 221 cases. The primary diseases were malignancy in 441 cases(colorectal cancer 252 cases, gastric cancer 54 cases, etc.)and benign diseases in 59 cases. Seven patients(1. 4%)had complications at implantation(pneumothorax 6 cases, catheter migration 1 case). Forty-three patients(8. 6%)had complications after port implantation. Among them, 18 suffered port infection, 10 had obstruction of the catheter system, 4 developed skin ulceration, 4 developed port rotation, 3 had venous thrombosis, and 3 developed catheter migration. The cumulative patency rates after 1, 2, and 3 years were 90. 7%, 81. 2%, and 74. 6%, respectively. Complications after port implantation were more frequently developed in home parenteral nutrition than in chemotherapy.
我们回顾性分析了2007年1月至2011年11月期间在我院植入皮下中心静脉导管（CV导管）的500例患者，以调查CV导管植入后出现的并发症。CV导管植入的目的是化疗通路279例，家庭肠外营养221例。原发性疾病为恶性肿瘤441例（结直肠癌252例、胃癌54例等），良性疾病59例。7例患者（1.4%）在植入时出现并发症（气胸6例、导管移位1例）。43例患者（8.6%）在导管植入后出现并发症。其中，18例发生导管感染，10例发生导管系统阻塞，4例出现皮肤溃疡，4例出现导管旋转，3例发生静脉血栓形成，3例出现导管移位。1年、2年和3年后的累积通畅率分别为90.7%、81.2%和74.6%。导管植入后并发症在家庭肠外营养患者中比化疗患者更常见。
